PURPOSE: To compare outcomes of patients with HIV-Burkitt's lymphoma (HIV-BL) and HIV-diffuse large-cell lymphoma (HIV-DLCL) after treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or M-BACOD (methotrexate, bleomycin, cyclophosphamide, etoposide) in pre-highly active antiretroviral therapy (HAART) versus HAART eras. PATIENTS AND METHODS: Three hundred sixty-three patients with AIDS-related lymphoma diagnosed from 1982 to 2003 were reviewed retrospectively, including 262 in the pre-HAART (HIV-BL, 117; HIV-DLCL, 145) and 101 in the HAART era (HIV-BL, 18; HIV-DLCL, 83). Pre-HAART included those who did not receive HAART, and HAART era included those diagnosed after January 1997 who received HAART. RESULTS: There were no significant differences between groups in terms of age, sex, history of injection drug use, prior AIDS, lactate dehydrogenase level, and disease stage at diagnosis. Compared with HIV-BL, HIV-DLCL was associated with significantly lower CD4 counts in the pre-HAART but not the HAART era. Although the overall median survival was similar for both groups in the pre-HAART era (HIV-BL, 6.4 months v HIV-DLCL, 8.3 months; P = .43), survival was significantly worse in patients with HIV-BL in the HAART era (HIV-BL, 5.7 months v HIV-DLCL, 43.2 months; P = .0003). Failure to attain complete remission and CD4 count less than 100 cells/mm(3) independently predicted for poor survival in the pre-HAART era. In comparison, histology of HIV-BL and no attainment of complete remission were independent poor prognostic factors in the HAART era. CONCLUSION: Survival of patients with HIV-DLCL has improved in the HAART era, along with CD4 count, whereas survival of similarly treated patients with HIV-BL remained poor. The current practice of using the same regimen for both groups of patients should be re-evaluated.
PURPOSE: To compare outcomes of patients with HIV-Burkitt's lymphoma (HIV-BL) and HIV-diffuse large-cell lymphoma (HIV-DLCL) after treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or M-BACOD (methotrexate, bleomycin, cyclophosphamide, etoposide) in pre-highly active antiretroviral therapy (HAART) versus HAART eras. PATIENTS AND METHODS: Three hundred sixty-three patients with AIDS-related lymphoma diagnosed from 1982 to 2003 were reviewed retrospectively, including 262 in the pre-HAART (HIV-BL, 117; HIV-DLCL, 145) and 101 in the HAART era (HIV-BL, 18; HIV-DLCL, 83). Pre-HAART included those who did not receive HAART, and HAART era included those diagnosed after January 1997 who received HAART. RESULTS: There were no significant differences between groups in terms of age, sex, history of injection drug use, prior AIDS, lactate dehydrogenase level, and disease stage at diagnosis. Compared with HIV-BL, HIV-DLCL was associated with significantly lower CD4 counts in the pre-HAART but not the HAART era. Although the overall median survival was similar for both groups in the pre-HAART era (HIV-BL, 6.4 months v HIV-DLCL, 8.3 months; P = .43), survival was significantly worse in patients with HIV-BL in the HAART era (HIV-BL, 5.7 months v HIV-DLCL, 43.2 months; P = .0003). Failure to attain complete remission and CD4 count less than 100 cells/mm(3) independently predicted for poor survival in the pre-HAART era. In comparison, histology of HIV-BL and no attainment of complete remission were independent poor prognostic factors in the HAART era. CONCLUSION: Survival of patients with HIV-DLCL has improved in the HAART era, along with CD4 count, whereas survival of similarly treated patients with HIV-BL remained poor. The current practice of using the same regimen for both groups of patients should be re-evaluated.
Authors: Ulas D Bayraktar; Juan Carlos Ramos; Adam Petrich; Neel Gupta; Shelly Lensing; P C Moore; Erin G Reid; David M Aboulafia; Lee Ratner; Ronald Mitsuyasu; Timothy Cooley; David H Henry; Paul Barr; Ariela Noy Journal: Leuk Lymphoma Date: 2012-07-09
Authors: Osama Qubaiah; Susan S Devesa; Charles E Platz; Mark M Huycke; Graça M Dores Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-07-20 Impact factor: 4.254
Authors: Stefan K Barta; Xiaonan Xue; Dan Wang; Jeannette Y Lee; Lawrence D Kaplan; Josep-Maria Ribera; Albert Oriol; Michele Spina; Umberto Tirelli; Francois Boue; Wyndham H Wilson; Christoph Wyen; Kieron Dunleavy; Ariela Noy; Joseph A Sparano Journal: Haematologica Date: 2014-08-22 Impact factor: 9.941
Authors: C L Davies; R Chinn; M Nelson; M Rasanesan; B Gazzard; T Powles; M Bower; J Stebbing Journal: AJNR Am J Neuroradiol Date: 2007-09-26 Impact factor: 3.825
Authors: Moses H Bateganya; Jeffrey Stanaway; Paula E Brentlinger; Amalia S Magaret; Anna Wald; Jackson Orem; Corey Casper Journal: J Acquir Immune Defic Syndr Date: 2011-04 Impact factor: 3.731
Authors: S K Barta; M S Samuel; X Xue; D Wang; J Y Lee; N Mounier; J-M Ribera; M Spina; U Tirelli; R Weiss; L Galicier; F Boue; R F Little; K Dunleavy; W H Wilson; C Wyen; S C Remick; L D Kaplan; L Ratner; A Noy; J A Sparano Journal: Ann Oncol Date: 2015-01-28 Impact factor: 32.976
Authors: Joyce C Mhlanga; Daniel Durand; Hua-Ling Tsai; Christine M Durand; Jeffrey P Leal; Hao Wang; Richard Moore; Richard L Wahl Journal: Eur J Nucl Med Mol Imaging Date: 2014-01-28 Impact factor: 9.236